Citations

1. North American Menopause Society (2004). Treatment of menopause-associated vasomotor symptoms: Position statement of the North American Menopause Society. Menopause, 11(1): 11–33.

2. Fitzpatrick LA (2003). Alternatives to estrogen. Medical Clinics of North America, 87(5): 1091–1113.

3. Zhang X, et al. (2005). Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Archives of Internal Medicine, 165(16): 1890–1895.

4. Speroff L, Fritz MA (2005). Menopause and the perimenopausal transition. In Clinical Gynecologic Endocrinology and Infertility, 7th ed., pp. 621–688. Philadelphia: Lippincott Williams and Wilkins.

5. Joffe H, et al (2003). Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatric Clinics of North America, 26(3): 563–580.

6. Mishell DR (2001). Menopause. In MA Stenchever et al., eds., Comprehensive Gynecology, 4th ed., pp. 1217–1258. St. Louis: Mosby.

7. Taguchi A, et al. (2004). Effect of estrogen use on tooth retention, oral bone height, and oral bone porosity in Japanese postmenopausal women. Menopause, 11(5): 556–562.

8. Rossouw JE, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3): 321–333.

9. Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382): 419–427.

10. Shumaker SA, et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: A randomized controlled trial. JAMA, 289(20): 2651–2662.

11. Rossouw JE, et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13): 1465–1477.

12. Stearns V, et al. (2003). Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA, 289(21): 2827–2834.

13. Pandya KJ, et al. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of Internal Medicine, 132(10): 788–793.

14. Watt PJ, et al. (2003). A holistic programmatic approach to natural hormone replacement. Family and Community Health, 26(1): 53–63.

15. North American Menopause Society (2005). The role of testosterone therapy in postmenopausal women: Position statement of the North American Menopause Society. Menopause, 12(5): 497–511.

16. Huntley AL, Ernst E (2003). A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause, 10(5): 465–476.

17. National Heart, Lung, and Blood Institute (2003). Postmenopausal hormone therapy: Questions and answers. Available online: http://www.nhlbi.nih.gov/health/women/q_a.htm.

18. American College of Obstetricians and Gynecologists (2003). Statement of the American College of Obstetricians and Gynecologists on hormone therapy for the prevention and treatment of postmenopausal osteoporosis. ACOG News Release. Available online: http://www.acog.com/from_home/publications/press_releases/nr10-07-03.cfm.

19. Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14): 1701–1712.

20. North American Menopause Society (2004). Abridged recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause Management, 13(6): 12–19. Also available online: http://www.menopausemgmt.com/issues/13-06/issue.html.

21. Beral V, et al. (2007). Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet, 369(9574): 1703–1710.

22. American College of Obstetricians and Gynecologists Women's Health Care Physicians (2004). Breast cancer. Obstetrics and Gynecology, 104(4, Suppl): 11S–16S.

23. American College of Obstetricians and Gynecologists Women's Health Care Physicians (2004). Stroke. Obstetrics and Gynecology, 104(4, Suppl): 97S–105S.

24. Speroff L, Fritz MA (2005). Postmenopausal hormone therapy. In Clinical Gynecologic Endocrinology and Infertility, 7th ed., pp. 689–777. Philadelphia: Lippincott Williams and Wilkins.

25. Grady D, et al. (2003). Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstetrics and Gynecology, 102(6): 1233–1239.

26. Irvin JH, et al. (1996). The effects of relaxation response training on menopausal symptoms. Journal of Psychosomatic Obstetrics and Gynecology, 17(4): 202–207.

27. Freedman R, et al. (1995). Biochemical and thermoregulatory effects of behavioral treatment for menopausal hot flashes. Menopause: The Journal of the North American Menopause Society, 2(4): 211–218.

28. Guttuso T Jr, et al. (2003). Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstetrics and Gynecology, 101(2): 337–345.

29. American College of Obstetricians and Gynecologists (2001). Use of botanicals for management of menopausal symptoms. ACOG Practice Bulletin No. 28. Obstetrics and Gynecology, 97(6, Suppl): 1–11.

30. Cooper A, et al. (1998). Systemic absorption of progesterone from Progest cream in post-menopausal women. Lancet, 351(9111): 1255–1256.

31. Hermann AC, et al. (2005). Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration-approved oral progesterone product. Journal of Clinical Pharmacology, 45(6): 614–619.

32. Prestwood KM, et al. (2003). Ultralow-dose micronized 17 B-estradiol and bone density and bone metabolism in older women. JAMA, 290(8): 1042–1048.

33. Balk E, et al. (2005). Effects of Soy on Health Outcomes. Evidence Report/Technology Assessment No. 126 (AHRQ Publication No. 05–E024–1). Rockville, MD: Agency for Healthcare Research and Quality. Also available online: http://www.ahrq.gov/clinic/epcsums/soysum.pdf.